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Glucose metabolism and the productton of 0; and NO; have been studied in peritoneal macrophages from mice Injected with 5 subdtabetogemc 
doses of streptozotocm. On day 12 after begmning of the treatment, perttoneal macrophages produced stgnificantly higher amounts of lactate than 
macrophagea from control mace. In addttion. NO; release and phorbol ester-Induced 0; productton were stgmticantly augmented in macrophages 
from streptozotocin-treated mace. y-Interferon Induced m a dose-dependent manner the acttvtty of NO synthase only m macrophages from 
streptozotocin-treated mace The,e data shou for the first time that peritoneal macrophages from streptozotocin-treated mice arc acttvated and 
produce effector molecules such as 0; and ‘NO vvhtch could participate m the destructton of pancreatic Islets. 
Nitric owtde. Superoxide anion. Diabetes; Macrophage; y-Interferon 
Macrophages play a pivotal role in the immune at- 
tack against the pancreatic islets in several animal mod- 
els of type I diabetes [1,2]. Recently. it has been shown 
that islet cell lysis induced by C. parrzarr-activated mac- 
rophages is mediated by ‘NO since cell destruction can 
be counteracted by NO synthase inhibitors [3]. How- 
ever, evidence concerning the activation state of macro- 
phages and the effector molecules that mediate islet 
destruction in experimental immune diabetes is lacking. 
By studying the production of lactate and the release of 
effector molecules such as 0; and ‘NO, we show for the 
first time that peritoneal macrophages from low-dose 
streptozotocin-treated mice are activated at a time when 
the immune destruction of the pancreatic islets is in 
progress. 
2. MATERIALS AND METHODS 
Male CD-1 mice (Charles Rover, Barcelona, Spain) weighing 75530 
g were used. Culture media were from ICN (Barcelona. Spain) FCS. 
anttbiottcs. streptozotocin (STZ), cytochrome c. Phorbol I?-myrtatate 
13-acetate (PMA). lactate dehydrogenase and NAD’were from Sigma 
(Alcobendas, Spain). Salts were from Merck (Barcelona. Spain). y- 
Interferon (IFN-y) and superoxtde dtsmutaae were from Boehrmger 
Mannhetm (Barcelona. Spatn). 
STZ was dtssolved m cold citrate buffer. pH 4.5. and InJected wtthm 
3 mm i.p. at a dose of 40 mg/kg on 5 consccuttve days 
2.2. Hurw.\r of‘nru~ro/~l~u.~r.\ 
Perttoncal macrophages were harvested by perttoneal lavage [4]. 
The viabtlity of the collected cells was estimated from then abthty to 
exclude Trypan blue and was aluays htgher than 95%. 
Peritoneal cells were resuspended m culture medium consisting of 
etther RPM1 1640 or EMEM without argnnne. 10% FCS and anttbt- 
ottcs and plated (8 x 10’ cells m 250~1) in flat bottom. 96-well culture 
plates and Incubated for 4X h at 37’C 
0; productton was measured as m [5]. Briefly. macrophages (IOh 
cells/ml) were Incubated at 37°C m Kreba-Ringer btcarbonate buffer 
contarning IO mM glucose and 80 ,uM cytochromc c. After 5 mm. 
100 nM PMA was added and superoutde dismutase-mhibttable decrease 
m absorbance at 550 nm was recorded contiuously. The rate of 0; 
generation was esttmated usmg a molar ab\orptton coefficient of 
21.1 mM_’ cm-’ 
Lactate accumulatton m medium was measured usmg a standard 
spectrophotometrtc assay [6] 
The accumulatton of NO; in culture supernatants was measured 
wtth the Grtess reagent [7]. Briefly. 100~150 ,uI of supernatant was 
mtxed with 500 ~1 of Grtess reagent. Absorbance was measured at 
550 nm NO; concentratton was calculated. from a NaNO, standard 
curve. 
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3. RESULTS 
Fig. 1 shows that the treatment with low-dose STZ 
induced an increase in the PMA-induced 0, production 
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Fig. 1. Evolution of superoxide anion production by perttoneal macro- 
phages from mace treated with low-dose STZ. Superoxide anion pro- 
ductton was measured at day 6 (o-0) and at day 12 (o--c). Control 
mice (o-o) received buffer alone. Values are means k S.E.M. for 
three expertments performed in triplicate. 
by peritoneal macrophages. On day 6 after beginning of 
the treatment with STZ, 02 production was increased 
79% over control. This increase was more evident when 
the time elapsed was 12 days (259% over control). 
Table I shows that NO; production is significantly 
increased in macrophages from the 12-day group. Lac- 
tate production by macrophages was also significantly 
higher than macrophages from control mice. 
Fig. 2 shows the IFN-y dependence of NO; produc- 
tion by macrophages cultured in EMEM medium with- 
out arginine. Under these conditions, basal NO, pro- 
duction by STZ-treated macrophages is significantly 
lower than control macrophages. IFN-I/ selectively 
stimulates NO, production by cultured STZ-treated 
macrophages in a concentration-dependent manner, 
since no effect of IFN-y was detected in control macro- 
phages. 
Table I 
Nitrite production and lactate output m macrophages from control 
and STZ injected CD-l mace 
NO, 
(nmol/well) 
Lactate 
@mol/well) 
Controls 1.86 I! 0.15 0.32 k 0.05 
STZ-treated 9.29 k 2.32* 0.90 + 0.12* 
Macrophages (5 x 10’ cells per well were collected from cttrate-in- 
jetted mice and from mice 12 days after the first STZ injection and 
cultured in RPM1 1640 for 48 h. Values are the means + S.E.M. from 
5 replicates and are representative of 4 separate experiments. 
*2P < 0.002. 
Table II shows the effect of IFN-y on NO; produc- 
tion by macrophages from E. c&treated mice. Follow- 
ing culture in EMEM medium without arginine for 
48 h. E. coli-activated macrophages produce significantly 
higher amounts of NO; than control macrophages. In 
addition, IFN-y (100 U/ml) specifically stimulated the 
production of NO; in E. co/i-activated macrophages. 
4. DISCUSSION 
The administration of multiple low doses of STZ to 
CD-I mice results in a progressive destruction of pan- 
creatic p-cells [8]. Macrophages have been reported to 
be the cells that initiate the immune attack against the 
pancreatic /?-cells in this experimental model [l]. We 
have found that peritoneal macrophages from STZ- 
treated mice display an enhanced production of 0; in 
response to PMA (Fig. 1). This increase in 0; genera- 
tion by macrophages is a consequence of their activa- 
tion and may affect pancreatic /?-cells since superoxide 
dismutase activity is low in these cells [9,10]. 
Peritoneal macrophages collected 12 days after begin- 
ning of the STZ treatment produced significantly higher 
amounts of lactate than macrophages from control mice 
(Table I). Similar findings have been reported in E. coli- 
and in C. parrum-activated macrophages and indicate 
that these cells metabolize glucose at high rate to supply 
energy for the activation processes [6,11]. ‘NO produc- 
tion (measured as nitrite accumulation in the culture 
medium) is also increased after STZ treatment at satu- 
30 
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IFN-gamma (U\mI) 
Ftg. 2. Effect of y-Interferon on NO, production by peritoneal mac- 
rophages. Macrophages (8 x lo5 cells per well) were Incubated for 
48 h with different amounts of IFN-y m EMEM medium wrthout 
arginine. Macrophages were from control mice (V-V). from STZ- 
Injected mace at day 12 (m-w) and from STZ-Injected mice at day 21 
(o-o) Data are means + S.E M. from triplicates and are representa- 
ttve of 223 expertments. 
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Table 11 
Effect of IFN-y on NO; production by E. co/i-activated macrophages 
NO; (nmol/well) 
Without IFN-y +I00 U/ml IFN-y 
Controls 2.28 * 0.03 2.29 f 0.06* 
E c&activated 6.09 + 0.20 10.17 * 0.39** 
Macrophages (5 x lo5 cells per well) from control mice and from E 
c&treated mice were cultured m an arginme free medium for 48 h in 
the presence of 100 U/ml IFN-?I. Values are means f SE M from 
triplicates and are representative of 2 experiments. 
*NS, **ZP < 0.001. 
rating concentrations of arginine (Table I). These re- 
sults show that NO is released by macrophages at a time 
when macrophage infiltration of the islet is in progress 
[l]. It is thus possible that the generation of ‘NO by 
activated macrophages is critical for the destruction of 
the B-cell in this model of immune mediated diabetes as 
is the case in C. parvunz-activated macrophages [3]. 
IFN-y is a potent inducer of ‘NO synthase by macro- 
phages from several strains of mice and rats and may 
play a regulatory role on the activation of macrophages 
during the immune attack to the B-cells [ 12.131. We have 
found that IFN-1/ stimulates selectively NO; produc- 
tion by macrophages from E. c&-treated mice and by 
macrophages from STZ-treated CD-1 mice (Table II 
and Fig. 2). It is thus entirely possible that IFN-y re- 
leased by helper lymphocytes located in the vicinity of 
pancreatic ,B-cells may modulate macrophage mediated 
islet cell destruction. 
In conclusion, our data show that peritoneal macro- 
phages are metabolically active and have an increased 
production of 0; and ‘NO at a time when immune 
attack to the endocrine pancreas is in progress. The 
actions of macrophages may be controlled by cytokines 
such as IFN-y released by lymphocytes in the vicinity 
of the p-cells in this experimental model of type I diabe- 
tes. 
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